Abstract

For treating relapsed mantle-cell lymphoma (MCL), the Bruton tyrosine kinase inhibitor ibrutinib has been approved in the U.S. and Europe, and the mTOR (mammalian target of rapamycin) inhibitor temsirolimus is approved in Europe. Investigators compared the two drugs in a multinational, open-label trial funded by ibrutinib's manufacturer. The researchers randomized 280 patients (median age, 68) with relapsed or refractory MCL to …

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call